



OPI DATE 09/09/98 APPLN. ID 61769/98  
AOJP DATE 05/11/98 PCT NUMBER PCT/US98/03235



AU9861769

<b>(51) International Patent Classification 6 :</b> A61K 31/20, 31/14, 31/66		<b>A2</b>	<b>(11) International Publication Number:</b> WO 98/36745
			<b>(43) International Publication Date:</b> 27 August 1998 (27.08.98)
<b>(21) International Application Number:</b> PCT/US98/03235		<b>(74) Agents:</b> BRAINARD, Thomas, D.; Ross Products Division, Abbott Laboratories, Dept. 108140/DS-1, 625 Cleveland Avenue, Columbus, OH 43215-1724 (US) et al.	
<b>(22) International Filing Date:</b> 19 February 1998 (19.02.98)			
<b>(30) Priority Data:</b> 08/804,700 21 February 1997 (21.02.97) US 08/825,314 28 March 1997 (28.03.97) US 08/943,576 3 October 1997 (03.10.97) US		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
<b>(71) Applicants:</b> ABBOT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION [US/US]; 1534 White Avenue, Knoxville, TN 37996 (US).		<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
<b>(72) Inventors:</b> CARLSON, Susan, E.; 4501 Holmes Road, Kansas City, MO 64110 (US). PONDER, Debra, L.; 8313 River Park Way, Evansville, IN 47715 (US). MONTALTO, Michael, B.; 4001 Fenwick Road, Columbus, OH 43220 (US). DOHNALEK, Margaret, H.; 1483 Buck Trail Lane, Worthington, OH 43085 (US). BENSON, John, D.; 10583 Wellington, Powell, OH 43065 (US). BORROR, David, A.; 6001 Sunlawn Drive, Westerville, OH 43081-3175 (US). DIODATO, David, V.; 8567 Scioto-Darby Creek Road, Hilliard, OH 43026 (US).			
<b>(54) Title:</b> METHODS AND COMPOSITIONS FOR REDUCING THE INCIDENCE OF NECROTIZING ENTEROCOLITIS			
<b>(57) Abstract</b> <p>Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), e.g. arachidonic acid (AA) and docosahexaenoic acid (DHA) essentially free of cholesterol, and a process for making such enteral compositions are described. More particularly, the invention relates to methods for reducing the incidence of necrotizing enterocolitis by administering compositions which provide n-6 and n-3 long chain PUFAs; phospholipids and/or choline. Compositions from egg yolk lipids are presently preferred as they contain n-6 and n-3 long chain PUFAs and are predominantly in a phosphatidylcholine form. This is believed to provide a synergistic effect. Also disclosed is a process of making such a composition that provides improved organoleptic and stability properties.</p>			

**METHODS AND COMPOSITIONS FOR REDUCING  
THE INCIDENCE OF NECROTIZING ENTEROCOLITIS**

5           The present invention relates generally to enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs) and to a process for making such enteral compositions and to methods of reducing the incidence of necrotizing enterocolitis. More particularly, the present invention relates to enteral compositions which provide long chain PUFAs arachidonic acid (AA) and docosahexaenoic acid (DHA) essentially  
10 free of cholesterol and may be derived from egg yolk lipids. Long chain PUFAs provided from egg yolk are predominantly in a phospholipid form. The process of making such a composition provides improved organoleptic and stability properties. Enteral administration of such compositions can reduce the incidence of necrotizing enterocolitis.

15

**Background of the Invention**

Long chain PUFAs in enteral formulas or compositions have been the subject of diverse literature. For example, U.S. Patent 4,670,285 ("Clandinin") discloses a specific fat blend suitable for use in infant formulas. More specifically, the Clandinin fat blend  
20 contains at least one C<sub>20</sub> or C<sub>22</sub> n-6 fatty acid and a C<sub>20</sub> or C<sub>22</sub> n-3 fatty acid. These fatty acids are disclosed as being at certain, defined amounts to avoid causing harmful effects to an infant fed the fat blend. The C<sub>20</sub> or C<sub>22</sub> n-6 fatty acids are present in a total amount of about 0.13 to 5.6% by weight of all fatty acids in the product. The C<sub>20</sub> or C<sub>22</sub> n-3 fatty acid, if present, are included in a total amount of about 0.013 to 3.33% by weight of all  
25 fatty acids in the product. Clandinin discloses the use of egg lipids to supply the n-6 and n-3 fatty acids; however, the egg lipid used by Clandinin also contains high levels of cholesterol. Further, this reference teaches the use of 75 to 95 parts by wt. of egg yolk lipid with the remainder of the oil being coconut oil or soybean oil. The nomenclature used by Clandinin for fatty acids will be utilized herein.

30           WO 93/20717 discloses an infant formula which contains no more than sub-irritant amounts of free long chain (C<sub>16</sub>-C<sub>22</sub>) fatty acids and triglycerides. This application also discloses that providing lower alkyl esters, such as ethyl esters, of such fatty acids in infant formula essentially eliminates the tendency of the free fatty acid to damage the intestinal epithelium of the infant, but permits absorption and processing of the fatty acid  
35 moiety.

U.S. Patent 4,918,063 to Lichtenberger discloses compositions containing unique mixtures of phospholipids and neutral lipids for the prevention or treatment of ulcers and inflammatory bowel disease. This patent discloses mixtures of saturated or unsaturated phospholipids, together with saturated or unsaturated triglycerides and/or sterols, as  
5 providing ulcer protective efficacy in experimental animal models. This patent also teaches the inclusion of polyvalent cations or antioxidants to the lipid mixture to enhance activity.

International Publication No. WO 96/10922 to Kohn et al. discloses a fat mixture for infant formula characterized in that arachidonic acid and docosahexaenoic acid are  
10 present in the fat mixture in the form of phospholipids.

European Patent Application 0 376 628 B1 to Tomarelli discloses an all vegetable oil fat composition which utilizes randomized palm oil or randomized palm olein oil as the sole palmitic acid oil source. It is also disclosed that the all vegetable oil fat compositions are particularly suited for use in infant formulas for pre-term (or low  
15 birth weight) infants. The pre-term fat compositions of the Tomarelli application include medium chain triglycerides (MCT's) with a randomized palmitic acid oil, lauric acid oil, an oleic acid oil and a linoleic acid oil.

Although the references discussed above have made important contributions, there remains a need for infant formulas that contain egg phospholipids as a source of  
20 long chain PUFAs in concentrations appropriate for nutrition. A further need remains for methods of preparing enteral formulas containing egg phospholipids such that the formulas have acceptable organoleptic properties. Such compositions have particular application in infant formula for term and/or preterm infants, whose needs for long chain PUFAs are established for the proper neural development and for development of visual  
25 acuity. In addition, there may be a protective effect on the gut.

Necrotizing enterocolitis (NEC) is a serious problem in infants having birth weights of less than about 1500 grams. Despite almost three (3) decades of study, the precise etiology and pathophysiology of NEC remains unclear. NEC is a  
30 life-threatening disease characterized by ischemic necrosis of the involved alimentary tract structures and pneumatosis intestinalis, which often results in the perforation of the bowel. A pre-term infant with NEC presents a clinical picture of thermal instability, lethargy, gastric retention, vomiting, abdominal distension, gross or occult blood in the stools and radiographic evidence of pneumatosis intestinalis, air in the portal veins or pneumoperitoneum. Apnea spells, shock and sclerema rapidly appear and death is  
35 common.

Numerous authors have made varied observations and posited factors influencing this malady. (Nue, *Pediatr. Clin. North. Am.*, April, 1996, 43(2): 409-32).

The following observations and factors are exemplary:

- 5 • Flageole et al., Necrotizing Enterocolitis of the Newborn, Review for the Clinician. Union-Med-Can. 1991 Sep-Oct; 120(5): 334-8, suggest the pathogenesis of NEC includes mesenteric ischemia, gastrointestinal immaturity, enteral feedings and even possibly infection;
- 10 • Caplan et al., Role of Platelet Activating Factor and Tumor Necrosis Factor-Alpha in Neonatal Necrotizing Enterocolitis, *Journal of Pediatrics*, June, 1990, 960-964, report platelet activating factor and tumor necrosis factor-alpha are elevated in patients with NEC;
- 15 • Kliegman et al., Clostridia as Pathogens in Neonatal Necrotizing Enterocolitis, *The Journal of Pediatrics*, August, 1979, 287-289, reports the isolation of *Clostridia perfringens* from children with neonatal NEC;
- 20 • Ostertag et al., Early Enteral Feeding Does Not Affect the Incidence of Necrotizing Enterocolitis, *Pediatrics*, Vol. 77, No. 3, March 1986, 275-280, reports that dilute, early enteral calories do not adversely affect the incidence of NEC;
- 25 • Bell et al., Neonatal Necrotizing Enterocolitis, *Annals of Surgery*, Vol. 187, January 1978, No. 1, 1-7, suggests the use of combination antimicrobial therapy for the treatment of infants with NEC;
- Eyal et al., Necrotizing Enterocolitis in the Very Low Birth Weight Infant: Expressed Breast Milk Feeding Compared with Parenteral Feeding, *Archives of Disease in Childhood*, 1982, 57, 274-276 reports that the incidence of NEC in low birth weight infants was reduced by delaying the initiation of enteral feeding.
- 30 • Finer et al., Vitamin E and Necrotizing Enterocolitis, *Pediatrics*, Vol. 73, No. 3, March 1984 suggests that administration of vitamin E to reduce the incidence of severe sequelae from retrolental fibroplasia may be associated with an increased incidence of NEC.
- Brown et al., Preventing Necrotizing Enterocolitis in Neonates, *JAMA*, Nov. 24, 1978, Vol. 240, No. 22, 2452-2454 reports that NEC can be virtually eliminated by the use of a slowly progressive feeding regimen.
- Kosloske, Pathogenesis and Prevention of Necrotizing Enterocolitis: A Hypothesis Based on Personal Observation and a Review of the Literature,

*Pediatrics*, Vol. 74, No. 6, Dec. 1984, 1086-1092, hypothesizes that NEC occurs by the coincidence of two of three pathological events: (1) intestinal ischemia; (2) colonization by pathogenic bacteria; and (3) excess protein substrate in the intestinal lumen.

5       Kosloske, *supra*, also reports that NEC is rare among infants fed only breast milk. In humans, breast milk plays a role in passive immunization of the neonatal intestine, and contains factors that promote the growth of *Bifidobacterium* in the intestinal flora. It is also reported that the beneficial contents of human milk may be adversely affected by freezing, pasteurization, or storage.

10       Thus, there is much debate about the etiology and treatment of NEC and there remains a need for compositions and methods that are better able to cure and/or reduce the incidence of this devastating and frequently fatal condition.

### Summary of the Invention

The present invention has many aspects. In a first aspect, the invention  
5 contemplates a method for reducing the incidence of necrotizing enterocolitis in an infant  
who is susceptible to necrotizing enterocolitis, said method comprising the administration  
of an effective amount of at least one long chain PUFA selected from the group of C<sub>20</sub>n-6  
fatty acids, C<sub>22</sub>n-6 fatty acids, C<sub>20</sub>n-3 fatty acids and C<sub>22</sub>ω-3 fatty acids. For example,  
the administration of arachidonic acid, an n-6 fatty acid, has been found to be effective.  
10 Administration may be enteral or parenteral. More preferably, a combination of n-6 and  
n-3 fatty acids, for example arachidonic acid and docosahexaenoic acid, are used  
together. Enteral administration is at a level of at least 1.0 mg of n-6 fatty acids per  
kilogram of infant weight per day. A more preferred embodiment uses a combination of  
n-6 and n-3 fatty acids at weight ratios of about 2:1 to about 4:1 and administers at least  
15 5.0 mg long chain n-6 fatty acids per day.

The method may be performed by feeding a sufficient amount of an enteral  
composition containing arachidonic acid and docosahexaenoic acid to deliver to said  
infant about 1.0 to about 60 mg per kg per day of arachidonic acid and about 0.25 to  
about 35 mg per kg per day of docosahexaenoic acid. More typical amounts are about  
20 5.0 to about 40 mg arachidonic acid and about 1.5 to about 20 mg docosahexaenoic  
acid per kg per day. Preferably, the weight ratio of arachidonic acid to docosahexaenoic  
acid ranges from about 2 to about 4. Preferably, the long-chain polyunsaturated fatty  
acids are in the form of phospholipids, especially phosphatidylcholine. Such  
phospholipids are present in high concentrations in egg lecithin and egg phosphatides.

25 Thus, in a further aspect, the invention provides a method for decreasing the  
incidence of necrotizing enterocolitis in an infant, said method comprising feeding to said  
infant a sufficient quantity of an enteral nutritional composition containing protein,  
carbohydrate and phospholipids to provide at least 1.0 mg of n-6 long-chain  
polyunsaturated fatty acids per day. Preferably, the feeding further provides at least 0.5  
30 mg n-3 long-chain polyunsaturated fatty acids per day and in the form of arachidonic  
acid and docosahexaenoic acid, respectively.

In another aspect, the invention provides a method for decreasing the occurrence  
of necrotizing enterocolitis in a human infant, said method comprising administering to  
the infant phospholipids in an amount effective to reduce the incidence of necrotizing  
35 enterocolitis.

Typically said phospholipids are administered to provide between about 60 and about 2400  $\mu$ moles, preferably between about 200 and about 1500  $\mu$ moles, most preferably between about 400 and about 1000  $\mu$ moles of phospholipids per kg day. The source of the phospholipids is not crucial; phospholipids derived from egg lecithin are suitable for this invention. Phospholipids are also readily available from animal membranes, including milk fat globule membrane. Other sources rich in phospholipids include soybean and other seed oils. When egg lecithin phospholipids are employed, the preferred amount to administer enterally is enough to result in at least 1.0 mg of long chain n-6 fatty acids per day. Preferably the egg phospholipid supplies arachidonic acid as a significant portion of n-6 fatty acids and preferably also supplies docosahexaenoic acid and/or other long chain n-3 fatty acids in the ratios mentioned above. This may have a synergistic effect. However, it is noted that the length and saturation of the fatty acids attached to the glycerol backbone in this "phospholipid" aspect of the invention are not crucial and fatty acids other than LCPUFAs may be employed here.

In yet another aspect, the invention provides a method for decreasing the occurrence of necrotizing enterocolitis in a human infant, said method comprising administering to the infant choline in an amount effective to reduce the incidence of necrotizing enterocolitis. Typically said choline is administered to provide between about 60 and about 1800  $\mu$ moles; more preferably between about 150 and about 1200  $\mu$ moles of choline per kg per day. The source of the choline is not crucial; phosphatidylcholine may be preferred and phosphatidylcholine derived from egg lecithin is suitable for this invention. Other sources rich in choline or phosphatidylcholine include soybean and other seed oils. When egg lecithin choline is employed, it is preferred to administer in combination with n-6 and/or n-3 fatty acids to result in at least 1.0 mg of long chain n-6 fatty acids per day. Preferably the egg lecithin supplies arachidonic acid as a significant portion of n-6 fatty acids and preferably also supplies docosahexaenoic acid and/or other long chain n-3 fatty acids in the ratios mentioned above. This may have a synergistic effect. However, as with the phospholipid aspect, the length and saturation of the fatty acids attached to the glycerol backbone of any phosphatidylcholine used in the invention are not crucial and fatty acids other than LCPUFAs may be employed here.

Alternatively, choline from non-phospholipid sources may be employed.

In addition, because of the beneficial effects seen in infants susceptible to enterocolitis, it may well be the case that beneficial effects are seen also in adults. Thus, a further aspect of the invention is the use of any of the above compositions in treating or preventing ulcerative colitis and related intestinal conditions in adults. Of

course dosing will be adjusted based on the increased weight of the adult patient and on other factors known in the art.

Other aspects of the invention, including enteral formulations and processes of making them, are described throughout the application. For example, in yet another aspect of the invention, a process for the production of an enteral formula comprising egg yolk phospholipids comprises the steps of:

- (a) providing dried egg phosphatide powder essentially free of cholesterol;
- (b) dispersing said phospholipid fraction in an aqueous phase to form a phospholipid dispersion; and
- (c) combining said phospholipid dispersion with slurries of other components of said enteral formula.

Preferably according to the process, the dispersion in aqueous phase provides egg phosphatide at about 2 to about 15 percent by weight; and preferably the egg phosphatide powder is added to water at about 20 to 50°C. This aspect may be used to produce an infant formula containing arachidonic acid and docosahexaenoic acid in the form of phospholipids, said enteral formula being produced by the process.

In yet another aspect, the invention provides a formula suitable for feeding infants, comprising protein, carbohydrates and lipids, the improvement characterized in a lipid blend comprising medium chain triglycerides and egg phospholipid, wherein said egg phospholipid is present at a level from about 1 wt.% to about 40 wt.% of the lipid blend and wherein said egg phospholipid is essentially free of cholesterol. Typically the egg phospholipid is present at a level of from 5 to 30 wt.% of the lipid blend and the formula arachidonic acid in a concentration of from about 10 to about 31 mg per 100 kcals. More preferably, the formula also includes docosahexaenoic acid in a concentration of from about 3 to about 16 mg per 100 kcals and arachidonic acid and docosahexaenoic acid are present in a ratio of about 4:1 to about 2:1.

According to a further aspect of this invention there is provided the use of one or more ingredients selected from the group consisting of:

- (a) at least one n-6 polyunsaturated fatty acid,
- (b) optionally, at least one n-3 polyunsaturated fatty acid,
- (c) at least one phospholipid, and
- (d) choline

in the preparation of a composition for reducing the incidence of necrotizing enterocolitis in an infant which is susceptible to necrotizing enterocolitis, wherein said ingredient is present at an effective amount in a daily dose of said composition.



According to another embodiment of this invention there is provided at least one n-6 polyunsaturated fatty acid, when used in reducing the incidence of necrotising enterocolitis in an infant.

8 According to a further embodiment of this invention there is provided the use of at least one n-6 polyunsaturated fatty acid, in the manufacture of a medicament or enteral formula for reducing the incidence of necrotising enterocolitis in an infant.

According to yet a further embodiment of this invention there is provided a phospholipid, when used in decreasing the incidence of necrotising enterocolitis in an infant.

10 According to yet another embodiment of this invention there is provided the use of a phospholipid, in the manufacture of a medicament or enteral formula for decreasing the incidence of necrotising enterocolitis in an infant.

According to another embodiment of this invention there is provided choline, when used in decreasing the incidence of necrotising enterocolitis in an infant.

15 According to a further embodiment of this invention there is provided the use of choline, in the manufacture of a medicament or enteral formula for decreasing the incidence of necrotising enterocolitis in an infant.

20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95



## Detailed Description of the Invention

### General Terminology

Fatty acids are hydrocarbon chains of various lengths, having a carboxylic acid at one end, thus making them somewhat polar and hydrophilic at this location, while being otherwise hydrophobic to varying degrees depending on the length of the hydrocarbon chain. Fatty acids are categorized by the length of the hydrocarbon chain. For example, chains of fewer than about 6 carbons are considered "short"; chains of about 6-18 carbons are "medium" and chains of 20 or more carbons are considered "long". Fatty acids may also have one or more double bonds which are points of "unsaturation" in the hydrocarbon chain. As used herein, the term "long chain PUFA" means a fatty acid of twenty carbon atoms or more having at least two carbon-carbon double bonds (polyunsaturated). The number and position of double bonds in fatty acids are designated by a convention of nomenclature. For example, arachidonic acid ("AA" or "ARA") has a chain length of 20 carbons and 4 double bonds beginning at the sixth carbon from the methyl end. As a result, it is referred to as "C<sub>20</sub>:4 n-6". Similarly, docosahexaenoic acid ("DHA") has a chain length of 22 carbons with 6 double bonds beginning with the third carbon from the methyl end and is designated "C<sub>22</sub>:6 n-3". Less prevalent long chain PUFAs are also known and some are listed in Tables I and IV (below the solid line divider).

"Glycerides" are complex lipids having a glycerol backbone esterified to fatty acids. A "triglyceride" (i.e. "triacylglycerol") has three esterified fatty acids, one to each hydroxyl site on the glycerol backbone. Di- and mono-glycerides have, respectively, two and one esterified fatty acid. A phosphoglyceride (i.e. "phospholipid" or "phosphatide" - all used interchangeably) differs from a triglyceride in having a maximum of two esterified fatty acids, while the third position of the glycerol backbone is esterified to phosphoric acid, becoming a "phosphatidic acid". In nature, phosphatidic acid is usually associated with an alcohol which contributes a strongly polar head. Two such alcohols commonly found in nature are choline and ethanolamine. A "lecithin" is a phosphatidic acid associated with the aminoalcohol, "choline", and is also known as "phosphatidylcholine". Lecithins vary in the content of the fatty acid component and can be sourced from, for example, eggs and soy. Cephalin (phosphatidylethanolamine), phosphatidylserine and phosphatidylinositol are other phosphoglycerides.

Phospholipids are commonly found in the membranes of all living systems.

Traditional sources of phospholipids are egg yolk and soya bean oil. Phospholipids may also be obtained from mammalian brain, kidney, heart and lung; or from milk fat globule

membranes. In addition, sources of microbial origin (single cell oils) such as algal and fungal oils may be used, particularly for the AA and DHA fatty acid components of phospholipids.

Hens' eggs are a relatively abundant source of lipids. Approximately 33% of the yolk of a hen's egg is lipid, of which about 67% is triglyceride, 28% is phospholipid, and the remainder is mostly cholesterol (percentages are by weight). These figures are approximate and will vary to some degree, depending on the diet, breed and conditions of the hens. Of the phospholipid fraction, approximately 75% is phosphatidylcholine, and approximately another 20% is phosphatidylethanolamine. The choline moiety makes up about 15 to 30% of each phospholipid molecule depending on the particular fatty acids attached. Thus, the choline content of egg phospholipid can vary from about 10% to about 25% by weight; or, on the basis of total egg lipid, from about 3 to about 7% by weight.

#### 15 **Compositions**

Compositions useful in the invention comprise n-6 and/or n-3 long chain PUFAs. The source of the long chain PUFA is not critical. Known sources of long chain PUFA include fish or marine oil, egg yolk lipid and phospholipids, single cell oils (e.g., algal oils and fungal oils), it being understood in the art that some sources are better than others for achieving higher amounts of specific long chain PUFAs. Other edible, semi-purified or purified sources of long chain PUFAs will be evident to persons skilled in the art. New sources of long chain PUFAs may be developed through the genetic manipulation of vegetables and oil-bearing plants, and the use of such recombinant products is also contemplated in the present invention.

The long chain PUFA may be provided in the composition in the form of esters of free fatty acids; mono-, di- and tri-glycerides; phosphoglycerides, including lecithins; and/or mixtures thereof. It may be preferable to provide long chain PUFAs in the form of phospholipids, especially phosphatidylcholine. A presently preferred source, at least when processed such that the organoleptic properties and cholesterol level are acceptable, appears to be egg yolk phospholipids, perhaps due to the high phospholipid and/or phosphatidylcholine content associated with egg derived PUFAs.

The n-6 and/or n-3 fatty long chain PUFA may be administered in the form of an intravenous (i.e. parenteral) solution, as can choline and phosphatidylcholine. An intravenous solution will preferably contain effective amounts of the PUFA, the phospholipid and/or the choline in a reasonable daily intake of parenteral solution. The

exact concentration, therefore, is highly variable depending on the anticipated intake volume and is significantly more concentrated in a bolus or small-volume parenteral than in a hydrating or nutritional based parenteral product. Parenteral compositions will generally include pharmaceutically acceptable vehicles and excipients, such as buffers, 5 preservatives, and the like.

The n-6 and/or n-3 fatty long chain PUFA and the choline and phospholipid may alternatively be administered in the form of an enteral composition. Enteral compositions containing the long chain PUFA, choline or phospholipid may be in the form of a solution or an emulsion of active ingredient; or in a nutritional matrix 10 comprising protein, carbohydrates, other fats, minerals and vitamins. Enteral compositions containing active components may provide either supplemental or complete nutritional support. The concentration of the long chain PUFA in the enteral composition can range from almost 100% by weight (as in the case of a bolus emulsion) to 0.5% by weight (as in the case of a nutritionally complete formula) of the composition 15 depending on the mode of administration and intended purpose. In complete nutritional formulas the concentration may be even lower if enough of the formula is administered to deliver effective amounts of the long chain PUFA.

A particularly preferred embodiment of this invention relates to an improved, nutritionally complete formula suitable for feeding to infants, including pre-term infants. 20 Such a preferred composition comprises protein, carbohydrates and lipids, wherein from about 6 to about 40 wt. % of the total lipid is egg phospholipid which is essentially free of cholesterol. The term "essentially free" means that the cholesterol content of the egg phospholipid is less than 0.1 wt. % and preferably less than 0.05 wt. % of total lipid.

Those skilled in the art will readily understand what is meant by an infant 25 formula. When diluted or reconstituted, if initially in concentrate or powder form, to the ready to feed state, a typical infant formula contains about 10-35 gms of protein per liter of formula; 20-50 gms of lipid per liter of formula; 60-110 gms of carbohydrates per liter of formula and other various components such as vitamins, minerals, fibers, emulsifiers and the like. For purposes of understanding the components of an infant formula and 30 methods for its production, the following U.S. patents are herein incorporated by reference: 1) U.S. Patent 5,492,899 to Masor et al.; 2) U.S. Patent 5,021,245 to Borschel et al.; 3) U.S. Patent 5,234,702 to Katz et al.; and 4) U.S. Patent 5,602,109 to Masor et al.; and 5) U.S. Patent 4,670,268 to Mahmoud. More specifically, this embodiment of the invention comprehends an infant formula containing about 40-50 35 gms of lipid per liter of formula wherein the lipid comprises a blend of medium chain

triglycerides and egg phospholipid that is essentially free of cholesterol. Typically, the lipid blend comprises from about 1-40 wt. %, more preferably about 5 to about 30 wt. %, of the egg phospholipid. This embodiment is specifically designed to provide long chain PUFAs selected from n-3 fatty acids and n-6 fatty acids, phospholipids, and/or choline in amounts beneficial to infants.

#### ***Process of making***

Since hens' egg yolks include both triglycerides and phosphatides, it may be preferable to process the egg yolks using organic solvents in a manner that separates the phosphatides from triglycerides, sterols (e.g. cholesterol) and other components. Various literature methods are suitable for this separation, at least in laboratory scale. Alternatively, such egg phosphatides essentially free of cholesterol are commercially available in dried powder form from Pfanstiehl, Inc. (Waukegan, IL) as Catalog No. P-123.

The egg phosphatide is then incorporated into the enteral composition of the present invention. Because of the lipid content, incorporation of the egg phosphatides into an enteral formula was expected to be facile in an oil phase. However, it was surprisingly discovered that these lipid-lipid dispersions were unacceptable and that preparation of an aqueous dispersion of the egg phosphatide resulted in improved product. Aqueous dispersions of about 2 -15 wt %, preferably about 3 to about 8 wt %, should be made in cool to ambient water (about 20-25°C) to provide the best results. Warmer water produced less acceptable organoleptic properties.

Separately, the carbohydrate, protein and lipid slurries that comprise the macronutrient source are prepared as is known in the art, and these slurries are mixed at about 130 to 140°C. Just prior to homogenization, the phosphatide dispersion is mixed with the remainder of the formula.

In a particularly preferred variation, prior to the addition of the phosphatide dispersion to the final product mix (just before homogenization) the phosphatide dispersion is de-aerated under a moderate vacuum. De-aeration may be effected by any mechanism but an atomizing de-aerator at about 15 inches Hg provided satisfactory results. This additional step has been shown to improve the organoleptic and olfactory properties of the final product, even more so than activated carbon filtration or a combination of the two (see Example III).

For making parenteral compositions useful in this invention, conventional sterile parenteral production technology may be used. It may be preferable in this case to

avoid the egg phosphatides and employ instead the triglyceride oils or fatty acid esters, such as may be found in recombinant or single cell oil sources.

**Industrial Utility**

5 Compositions of the present invention are useful in the nutritional support of infants and/or adults. The addition of long chain PUFAs, especially n-6 and n-3 fatty acids and most especially AA and DHA have generally been considered to be beneficial to neural development and visual acuity of the infant, although conflicting reports have also been found in the literature.

10 Compositions useful in the present invention include those containing any or all of the following:

(a) long chain PUFAs selected from n-6 and n-3 fatty acids, typically in phospholipid or phosphatidylcholine form;

(b) polar phospholipids, regardless of the nature or length of the attached  
15 fatty acids;

(c) choline, preferably phosphatidylcholine.

For example, the egg phospholipid fortified formula described in detail in the examples provided higher levels of each of the specified components and surprisingly was found to reduce substantially the incidence of NEC in infant populations that are susceptible to  
20 NEC. In a more specific embodiment, the method of reducing the incidence of NEC is accomplished through the administration of arachidonic acid (AA, 20:4 n-6) or, more preferably, AA in combination with docosahexaenoic acid (DHA, 22:6 n-3).

More broadly, this aspect of the invention contemplates a method for reducing the incidence of necrotizing enterocolitis in an infant which is susceptible to necrotizing  
25 enterocolitis, said method comprising the administration of an effective amount of at least one long chain PUFA selected from the group of C<sub>20</sub>n-6 fatty acids, C<sub>22</sub>n-6 fatty acids, C<sub>20</sub>n-3 fatty acids and C<sub>22</sub>n-3 fatty acids. The administration is at a level of at least 1.0 mg of n-3 fatty acids per kilogram of infant weight per day. A more preferred embodiment uses a combination of n-6 and n-3 fatty acids at weight ratios of about 2:1  
30 to about 4:1.

There is further disclosed a method for decreasing the occurrence of necrotizing enterocolitis in a human infant, said method comprising administering to the infant egg phospholipids in an amount to result in at least 1.0 mg of long chain n-6 fatty acids per day. Preferably the egg phospholipids supplies AA as a significant portion of the n-6

fatty acids and preferably also supplies DHA and/or other long chain n-3 fatty acids in the ratios mentioned above.

An additional aspect of this invention relates to the enteral administration to humans of phospholipids, especially phospholipids containing AA and/or DHA which readily increase the blood serum levels of fatty acids AA and DHA in humans relative to compositions having triglycerides of AA and DHA.

A more appropriate measure of administration of compositions according to the invention is as daily intake in mg per kg infant body weight. The following Table A gives guidelines for minimum, preferred and ideal target ranges for each of the compositions useful in the invention.

Table A - Daily Intake Guidelines  
(based on per kg infant weight)

Component	minimum	preferred	more preferred	ideal target
AA, mg	1	2 to 60	5 to 40	10 to 30
DHA, mg	0.25	0.5 to 35	1.5 to 20	3 to 15
AA/DHA ratio	0.25	0.5 to 10	1 to 8	2 to 4
phospholipid, $\mu$ moles	50	60 to 2400	200 to 1500	400 to 1000
choline, $\mu$ moles	50	60 to 1800	150 to 1200	300 to 900

There is a wide variance in the ranges largely due to the fact that not all infants who are likely to benefit from this invention will consume equal volumes of formula. Those who consume less, received less of each ingredient. The ideal target ranges assume approximately 100 kcals will be consumed. Also, there is controversy about the methods for estimating the choline content.

It can be seen from Table A that most preferably there is about 2 to 4 times more AA than DHA. It is also observed that the minimum levels of phospholipid and choline are identical. This is attainable by providing all the phospholipid as phosphatidylcholine. As other nitrogenous alcohols replace the choline, (eg. ethanolamine, serine or inositol) the relative amount of choline to total phospholipid decreases.

The AA and/or DHA can be administered individually, as separate components, or together, or in combination with other ingredients such as protein, lipid, carbohydrate, vitamins and minerals. Nutritional support for low birth weight infants is either parenteral (intravenous feeding) or enteral. Thus, the appropriate levels of long chain PUFA can be incorporated into the parenteral nutrition solution or added to a conventional low birth weight enteral formula. Most preferably, the method of the present invention is accomplished through the enteral administration of an infant formula designed for low

birth weight infants containing AA and DHA. Such an infant formula further comprises appropriate levels of carbohydrate and protein and an appropriate combination of minerals and vitamins. An exemplary infant formula for use in the methods of the present invention is a modified Similac Special Care® (Ross Products Division of Abbott Laboratories, Columbus, Ohio), which is discussed in more detail in Example II.

An additional aspect of this invention is a method for increasing the blood serum levels of arachidonic acid and docosahexaenoic acid in human blood serum, said method comprising the step of administering to said human an enteral formula containing AA and DHA in the form of phospholipids.

10

Recent studies by the present Applicants have indicated that the administration of long chain PUFA, to infants susceptible to NEC will reduce the incidence of NEC and may also reduce the level or severity of NEC. The Applicants have also discovered that the administration of phospholipids from animal or vegetable sources is also effective in reducing the incidence of NEC in infant populations that are susceptible to NEC.

15

#### EXAMPLE I

Egg yolk phosphatide was obtained from Pfanstiehl, Inc. (Waukegan, IL - Catalog No. P-123) and was used in the following Examples. The fatty acid and cholesterol profile of this egg phosphatide is set forth in Table I. The sum of all n-3 and of all n-6 "long chain" PUFAs is also given.

20

TABLE I: Fatty Acid Profile and Cholesterol Content of Egg Yolk Lecithin

Fatty Acid	gm/100 gm of sample	
C14:0	0.08	
C16:0	18.83	
C16:1 n-7	0.82	
C16:4	0.21	
C18:0	6.72	
C18:1 n-9	17.36	
C18:2 n-6	9.8	
C20:1 n-9	0.11	
C20:2 n-6		0.24
C20:3 n-6		0.3
C20:4 n-6 - arachidonic		4.93
C22:0	0.07	
C22:4 n-6		0.3
C22:5 n-6		1.45
C22:5 n-3	0.09	
C22:6 n-3 - docosahexaenoic	1.24	
cholesterol	<0.05	
Total LCPUFA n-6		7.22
Total LCPUFA n-3	1.33	

Those skilled in the art will appreciate that the specific levels of the various fatty acids contained in egg yolk lipid will vary depending on the breed, diet and age of the hen. In addition, the extraction procedure used by Pfanstiehl to prepare the phosphatide used in the Examples results in a material that contains extremely low levels of cholesterol while possessing a fatty acid profile that is highly useful in the nutritional arts.

#### EXAMPLE II

In this example, "Experimental" and "Control" infant formulas were prepared, respectively, with and without the egg phosphatide of Example I. The Control composition was Similac Special Care® (Ross Products Division of Abbott Laboratories, Columbus, Ohio) and was prepared using the following list of ingredients, which results in the formula having the composition set forth in Tables II - IV, below:

Water (Kosher), nonfat milk, hydrolyzed cornstarch, lactose, fractionated coconut oil (medium-chain triglycerides), whey protein concentrate, soy oil, coconut oil, calcium phosphate tribasic, potassium citrate, sodium citrate, magnesium chloride, ascorbic acid, mono- and diglycerides, soy lecithin, calcium carbonate, carrageenan, choline chloride, ferrous sulfate, m-inositol, taurine, niacinamide, L-carnitine, alpha-tocopherol acetate, zinc sulfate, calcium pantothenate, potassium chloride, cupric sulfate, riboflavin and vitamin A palmitate, thiamin chloride hydrochloride, pyridoxine hydrochloride, biotin, folic acid, manganese sulfate, phyloquinone, vitamin D<sub>3</sub>, sodium selenite and cyanocobalamin.

Generally, protein, carbohydrate, lipid, vitamin and mineral slurries are separately prepared and then these are mixed prior to homogenization as is generally taught in the previously incorporated US patents relating to the manufacture of infant formula.

In the experimental formula, the egg phosphatide of Example I was incorporated into the formula during manufacture. First, the egg phosphatide was dispersed in water at 25°C to make an 8 % dispersion. Just prior to homogenization the phosphatide dispersion was combined with the protein, carbohydrate, vitamin, mineral and other lipid slurries to result in an "Experimental" formula having the composition shown in Tables II - IV, below. The amounts of each component are given both on a "per Liter" basis and on a "per kcal" basis since it is well known in the art to prepare infant formulas having higher or lower caloric densities than the standard 20 kcal per fluid ounce.

TABLE II: COMPONENTS of CONTROL AND EXPERIMENTAL FORMULAS

Nutrient	Preferred Ranges	
	Units Per Liter*	Units per 100 kcal
Protein, g	21.9 - 23.4	2.61 - 2.88
Fat, g (as described in Table III below)	40.0 - 46.0	5.24 - 5.67
Carbohydrate, g	84.0 - 88.0	10.00 - 10.84
[Ash, g]	6.7 - 8.0	0.80 - 0.99
Total Solids, g	158.6 - 165.0	18.88 - 20.32
Linoleic Acid, g	5.6 - 12.2	0.67 - 1.50
Calcium, mg	1300 - 1700	154.76 - 209.36
Phosphorus, mg	720 - 970	85.71 - 119.46
Magnesium, mg	100 - 170	11.90 - 20.94
Sodium, mg	349 - 389	41.55 - 47.91
Potassium, mg	1000 - 1420	119.05 - 174.88
Chloride, mg	650 - 770	77.38 - 94.83
Iron, mg	3.0 - 5.5	0.36 - 0.68
Zinc, mg	12.0 - 14.6	1.43 - 1.80
Copper, mg	2.0 - 3.0	0.24 - 0.37
Manganese, mcg	100 - 500	11.90 - 61.58
Iodine, mg	0.05 - 0.30	0.01 - 0.04
Selenium, mcg	12 - 29	1.43 - 3.57
Vitamin A, IU	6000 - 8000	714.29 - 985.22
Vitamin D, IU	1200 - 1580	142.86 - 194.58
Vitamin E, IU	35.0 - 45	4.17 - 5.54
Vitamin K <sub>1</sub> , mcg	100 - 140	11.90 - 17.24
Vitamin C, mg	350 - 450	41.67 - 55.42
Thiamin (B <sub>1</sub> ), mg	2.66 - 4.6	0.32 - 0.57
Riboflavin (B <sub>2</sub> ), mg	5.03 - 9.0	0.60 - 1.11
Pyridoxine (B <sub>6</sub> ), mg	2.6 - 3.4	0.31 - 0.42
Vitamin B <sub>12</sub> , mcg	4.47 - 9.5	0.53 - 1.17
Pantothenic Acid, mg	15.4 - 24.0	1.83 - 2.96
Folic Acid, mcg	340 - 450	40.48 - 55.42
Niacin, mg	40.6 - 65	4.83 - 8.00
Biotin, mcg	350 - 460	41.67 - 56.65
Choline, mg	81 - 243	9.64 - 29.93
m-Inositol, mg	44.7 - 61	5.32 - 7.51
L-Carnitine, mg	35 - 60	4.17 - 7.39
Taurine, mg	60 - 80	7.14 - 9.85
Energy (kcal)	812 - 840	

\* assumes 24 kcal per fluid oz.

The following Table III sets forth the lipid content (the only variable) used in the Control and Experimental products. It can be seen that the two formulas have the same total lipid amount, but differ principally in the exchange of egg phospholipid for a portion of the medium chain triglycerides. This substitution brings significantly higher levels of phospholipids and choline as well as additional long chain PUFAs.

**TABLE III: Lipids for Control and Experimental Formulas**

Ingredient	Control	Experimental
Lipid Blend	wt %	wt %
MCT*	50	41
coconut oil**	30	30
soy oil	20	20
egg phospholipid	0	9 (4.0 gm/L)
as choline		75% of 9%
as ethanolamine		20% of 9%
soy lecithin	0.45 gm/L	0.0 gm/L
Cholesterol	ND <sup>+</sup>	ND <sup>+</sup>
<b>Total Lipid (g/L)</b>	<b>44.1</b>	<b>44.1</b>

10

\* MCT = medium chain triglycerides

\*\* fractionated

+ ND = none detected

Table IV sets forth the composite fatty acid profile for the Control and Experimental formulas. This represents the sum of the fatty acid components of the egg lecithin and the Similac Special Care<sup>®</sup> formula.

TABLE IV: Average Fatty Acid Profiles in Weight %

Fatty Acid point of unsaturation	Control			Experimental		
	n-3	other	n-6	n-3	other	n-6
6:0 - caproic		0.71			0.27	
8:0 - caprylic		30.56			23.11	
10:0 - capric		19.61			16.44	
12:0 - lauric		9.69			10.24	
14:0 - myristic		3.85			4.08	
15:0 and 14:1		0.04			0.01	
16:0 - palmitoleic		5.51			7.65	
16:1 - palmitoleic		0.03			0.12	
16:2		-			-	
17:0 - margaric		0.04			0.09	
16:3		-			-	
16:4		-			-	
18:0 - stearic		2.68			3.89	
18:1 n-9 - oleic		8.31			11.25	
18:2 n-6 - linoleic			16.36			18.87
18:3 n-6 - linolenic			2.3			-
18:3 n-3	2.24			2.45		
18:4 n-6			-			0.02
20:0 - arachidic		0.12			0.14	
20:1 n-9		0.04			0.09	
20:2 n-9		0.02			0.02	
20:3 n-9		-			0.05	
20:4 n-6 - AA			-			0.41
20:4 n-3	-		-			
20:5 n-3	-		-			
22:0 - behenic		0.07			0.12	
22:5 n-6			-			0.07
22:5 n-3				0.07		
22:6 n-3 - DHA				0.14		
24:0		0.04			0.07	
Total LC PUFA n-3	0			0.21		
Total LC PUFA n-6			0			0.48
Total n-3	2.24			2.66		
Total n-6			18.66			19.37

- 5 The inclusion of the egg phosphatide resulted in 0.21 weight percent of the total lipid blend as long chain n-3 fatty acids and 0.48 weight percent of the total lipid blend as long chain n-6 fatty acids. More specifically, 0.14 weight percent of the total fat blend was DHA and 0.41 weight percent of the total lipid blend was AA. Based on administration of 100 kcal/kg/day for a 1 kg infant, this formula provides about 22 mg of
- 10 AA and about 7 mg of DHA per day. Of course this is just one possible embodiment of ratios within the invention.

**EXAMPLE III**

In this experiment, process variables were evaluated in an effort to reduce the organoleptic drawbacks associated with the use of egg phospholipids. The isolation of egg phospholipids useful in the present invention often results in an egg phosphatide  
5 that has somewhat objectionable organoleptic properties for use in an infant formula. These can be improved yet further to provide a product that is not objectionable to either the infant or the care giver. This process to improve the final product is described below.

A number of nutritional formulas similar to Example II were prepared except that  
10 6% by wt. of the fat blend was egg phospholipid which was pre-treated using various procedures. Egg phospholipid was dispersed in a portion of the oil blend described in Example II or in a portion of the water. The oil dispersions were unacceptable and could not be used even after heating to about 95°C. The dispersion of the phospholipid into water from ambient to warm temperature was accomplished easily and is the preferred  
15 means of forming the water dispersion.

A master batch of 3% by wt. egg phospholipid dispersion was prepared by blending the phospholipid in 90°C water for about 1 hour. A portion of this dispersion was passed through: (1) a de-aerator alone; (2) a carbon filtration unit alone; (3) a de-aerator and a carbon filtration unit combined; or (4) no treatment.

20 The activated carbon filtration unit contained 80 gms of activated carbon and the de-aeration unit was operated at a moderate vacuum (15 in. Hg). The batch portions were passed through the filtration unit 3 times and through the de-aerator once. When both techniques were used, the portion was passed through the filter first, then the de-aerator. The treated portions were then added to respective nutritional formulas just  
25 prior to homogenization and sample packaging.

The samples were then initially evaluated for "flavor notes" (organoleptic properties) by a panel of trained evaluators. The results of the panel are set forth in Table V.

**TABLE V: Infant Formula with Egg Yolk Phospholipids**

## Organoleptic Quality Results

Flavor Notes \*

Treatment of Dispersion	Initial	AA	AAL at 3 months	
De-aeration alone	AA	1 - 2.5	AAL	2.5
Carbon Filtration alone	AA	1.5 - 2	AAL	2.5
De-aeration/Carbon Filtration	AA	2	AAL	2.5
No Treatment	AA	2.5 - 3	AAL	3

5

\* Flavor Notes AA = Arachidonic Acid  
 AAL = Arachidonic Acid Lingering  
 + Scale 0.5 Very slight; 1 Slight; 1.5 Slight to Moderate; 2 Moderate; 2.5 Moderate to Strong; and 3 Strong

10 Surprisingly, the least aromatic sample was that which contained the dispersion that was passed through the de-aerator only. The dispersion that was passed through the de-aerator and the carbon filter had the poorest rating except for the control (no treatment of phospholipid dispersion).

15

**EXAMPLE IV**

Formulas prepared in accordance with Examples II and III were fed to infants in a study conducted in the Neonatal Nursery of the University of Tennessee Newborn Center under the direction of Dr. Susan E. Carlson with financial support from Ross Products Division of Abbott Laboratories (Study AE78), NICHD grant RO1-HD31329,  
 20 and National Eye Institute grant RO1-EY08770. Research parameters included growth, neural development, and visual acuity. Long chain PUFAs are believed to be physiologically important for the development of the brain and eye, and are rapidly accumulated in fetal tissues in the last trimester of pregnancy. Thus, pre-term infants do not accrete normal levels of long chain PUFAs relative to term infants.

25 Inclusion criteria: Entry into this clinical study was based on a "low" birth weight of less than 1500 gm (range 750-1375 gm) with no evidence of cardiac, respiratory, gastrointestinal or other systemic disease. The infant also had no history of birth asphyxia or clinical complications of blood group incompatibility. The mothers of the enrolled infants had no medical history of prenatal infections with proven adverse effects  
 30 on the fetus. Maternal substance abuse was an exclusion criteria. All infants initiated oral feedings by day 7 of life.

During the clinical study, a total of 120 infants were enrolled within the first 7 days of life. With the exception of one infant who was transferred to another hospital shortly after enrollment (Control), all other infants (n-119) were cared for in the same  
 35 hospital. Infants were enrolled (randomized, blind) into 1 of 3 groups, two of which

received the Control formula during their hospitalization and one of which received the Experimental formula (see Example II). Infants lost during hospitalization were replaced by another infant assigned to the same treatment group. Because of the study design, more infants were fed the Control formula. The total number fed the Control formula  
 5 was more than twice the number fed the Experimental formula.

**Findings:** An unanticipated finding was that a higher incidence of necrotizing enterocolitis (NEC) was seen in the Control Groups than the Experimental Group. Table VI groups the total number of neonates according to treatment (Control v. Experimental) and sets forth the number of neonates in each group that developed NEC. NEC was  
 10 considered present or suspect when clinical signs and symptoms consistent with this disease, such as abdominal distention, gastric residuals, bilious vomiting, heme positive stools, presence of mucosa in stools, and presence of C-reactive protein at  $\geq 0.5$  mg/dL (Pourcyrous et al., "Significance of Serial C-reactive Protein Responses in Neonatal Infection and Other Diseases", *Pediatr.*, 1993, 92:431-435). NEC was confirmed in 15  
 15 of the Control infants and only 1 of the Experimental group.

TABLE VI: Results of Clinical Study

	Control	Experimental
NEC*	15	1
no NEC	70	33
TOTAL	85	34

\* or suspected of NEC

20 Statistical analysis of this data, using Fisher's exact test (two tailed), shows that the number of infants confirmed with NEC in the Control treatment group(s) was significantly greater ( $p=0.039$ ) than the number of infants in the Experimental treatment group having NEC.

#### 25 EXAMPLE V

In this experiment, the inclusion of AA and DHA into parenteral (intravenous feedings) administration of nutrition, is evaluated. The parenteral solution can contain the various components known in the art with the AA and DHA being supplied in the form of a phospholipid, triglycerides or the methyl esters. The AA and DHA may be the  
 30 sole active ingredients admixed with conventional parenteral vehicles and excipients or, more preferably, the AA and DHA is included a parenteral formula intended to supplement or supply the total nutritional support of the infant. Typical parenteral nutritional solutions contain levels of lipids resulting in about 2 g/kg/day. The level of AA

and DHA in the lipid blend should preferably result in the administration of from 10 to 30 mg/kg/d of AA and 3 to 15 mg/kg/d for DHA.

#### EXAMPLE VI

5 In this experiment, the egg lecithin of the experimental formula of Example II is replaced by soy lecithin at the approximately ten-fold higher levels than found in the control formula. Soy lecithin, like other phospholipids derived from vegetable sources, contain no long-chain polyunsaturated acids; however, the polar nature of phospholipids and their ability to be readily incorporated into the intestinal mucosa may afford a  
10 protective effect on the intestinal lining, thereby producing results comparable to those of the experimental formula of Example II. Additionally, soy lecithin contains linoleic acid (18:2n-6 -- a dietary essential fatty acid precursor to AA) and linolenic acid (18:3n-3 -- a dietary essential fatty acid precursor DHA).

#### EXAMPLE VII

15 In this experiment, the use of phospholipids containing AA and DHA in infant formula is compared to triglycerides containing AA and DHA. The formula of Example II is compared to a similar infant formula wherein the egg phospholipid is replaced with a mixture of single cell microbial triglycerides containing comparable levels of AA and  
20 DHA.

Healthy full term infants are enrolled in a clinical evaluation to measure the blood serum levels of AA and DHA following enteral administration. It is expected that infants fed the phospholipid formula will achieve blood serum levels of AA and DHA more closely resembling those of breast fed infants than the control formula containing AA  
25 and DHA in triglyceride form. This experiment should demonstrate that phospholipids containing AA and DHA are a preferred form of administration over triglycerides containing AA and DHA. Thus, improved enteral formulas and methods for increasing AA and DHA blood serum levels are contemplated herein.

30 Modifications and alternative embodiments of the compositions and methods of the present invention will be apparent to those skilled in the art in view of the foregoing description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those of skill in the art the manner of carrying it out. The full scope of the invention for which protection is sought is defined in the appended claims.

**The claims defining the invention are as follows:**

1. A method for reducing the incidence of necrotising enterocolitis in an infant, said method comprising administering to an infant which is susceptible to necrotising enterocolitis an effective amount of at least one n-6 polyunsaturated fatty acid.
2. At least one n-6 polyunsaturated fatty acid, when used in reducing the incidence of necrotising enterocolitis in an infant.
3. At least one n-6 polyunsaturated fatty acid, when used according to claim 2 wherein said n-6 polyunsaturated fatty acid is in the form of a phospholipid.
4. Use of at least one n-6 polyunsaturated fatty acid, in the manufacture of a medicament or enteral formula for reducing the incidence of necrotising enterocolitis in an infant.
5. The method according to claim 1, wherein said at least one n-6 polyunsaturated fatty acid includes arachidonic acid.
6. The method according to claim 5, wherein said administration is performed enterally.
7. The method according to claim 5, wherein said administration is performed parenterally.
8. The method according to any one of claims 1, 5-7, wherein said at least one n-6 polyunsaturated fatty acid is administered in combination with at least one n-3 polyunsaturated fatty acid.
9. The method according to claim 8, wherein said n-3 polyunsaturated fatty acid comprises docosahexaenoic acid.
10. The method according to claim 8, wherein said n-6 polyunsaturated fatty acid comprises arachidonic acid and said n-3 polyunsaturated fatty acid comprises docosahexaenoic acid.
11. The method according to claim 10, wherein said administration is performed by feeding a sufficient amount of an enteral composition containing arachidonic acid and docosahexaenoic acid to deliver to said infant about 1.0 to about 60mg per kg per day of arachidonic acid and about 0.25 to about 35mg per kg per day of docosahexaenoic acid.
12. The method according to claim 11, wherein the weight ratio of arachidonic acid to docosahexaenoic acid ranges from about 2 to about 4.
13. The method according to claim 8, wherein said n-6 polyunsaturated fatty acid and said n-3 polyunsaturated fatty acid are long chain fatty acids independently selected from one or more sources selected from the group consisting of egg lecithin, fungal oils, algal oils and marine oils.



14. The method according to claim 8, wherein said n-6 polyunsaturated fatty acid and said n-3 polyunsaturated fatty acid are in the form of phospholipids.

15. The method according to claim 7, wherein said parenteral solution comprises at least 20mg of arachidonic acid per litre and at least 10mg of docosahexaenoic acid per  
5 litre.

16. The method according to claim 15, wherein said solution comprises per litre about 20 to about 200mg of arachidonic and about 10 to about 50mg of docosahexaenoic acid.

17. The method according to any one of claims 1, 5-16, comprising feeding to  
10 said infant a sufficient quantity of an enteral nutritional composition containing protein, carbohydrate and phospholipids to provide at least 2.0mg of n-6 polyunsaturated fatty acids per kg per day.

18. The method according to claim 17, wherein said feeding further provides at least 0.5mg n-3 polyunsaturated fatty acids per kg per day.

19. The method according to claim 18, wherein said feeding provides at least  
15 2.0mg arachidonic acid and at least 0.5mg docosahexaenoic acid per kg per day.

20. The method according to claim 19, wherein said enteral composition comprises egg phospholipid.

21. A method for decreasing the incidence of necrotising enterocolitis in an  
20 infant, said method comprising administering an effective daily amount of phospholipids to an infant susceptible to necrotising enterocolitis.

22. A phospholipid, when used in decreasing the incidence of necrotising enterocolitis in an infant.

23. A phospholipid when used according to claim 22 wherein said phospholipid is  
25 used in combination with arachidonic acid.

24. Use of a phospholipid, in the manufacture of a medicament or enteral formula for decreasing the incidence of necrotising enterocolitis in an infant.

25. The method of claim 21, comprising administering a sufficient quantity of said nutritional composition to provide between about 60 and about 2400 $\mu$ mole of  
30 phospholipids per kg day.

26. The method of claim 25, comprising administering a sufficient quantity of said nutritional composition to provide between about 200 and about 1500 $\mu$ mole of phospholipids per kg per day.

27. The method of claims 21, 25 or 26, wherein said phospholipids are derived from egg lecithin.



28. The method of claim 25, wherein said phospholipids are administered in combination with one or more polyunsaturated fatty acids selected from the group consisting of arachidonic acid and docosahexaenoic acid.

29. The method of claim 28, wherein said phospholipids are administered in combination with arachidonic acid and docosahexaenoic acid to give from about 200 to about 1500 $\mu$ mole of phospholipid; from about 5.0mg to about 40mg arachidonic acid; and from about 1.5mg to about 20mg docosahexaenoic acid per kg per day.

30. A method for decreasing the incidence of necrotising enterocolitis in an infant, said method comprising administering an effective daily amount of choline to an infant susceptible to necrotising enterocolitis.

31. Choline, when used in decreasing the incidence of necrotising enterocolitis in an infant.

32. Choline, when used according to claim 31 wherein said choline is used in combination with arachidonic acid.

33. Use of choline, in the manufacture of a medicament or enteral formula for decreasing the incidence of necrotising enterocolitis in an infant.

34. The method of claim 30, comprising administering a nutritional composition containing said choline in a sufficient quantity to provide between about 60 and about 1800 $\mu$ moles of choline per kg per day.

35. The method of claim 34, comprising administering a sufficient quantity of said nutritional composition to provide between about 150 and about 1200 $\mu$ mole of choline per kg per day.

36. The method of any one of claims 30, 34 or 35, wherein said choline is in the form of phosphatidylcholine.

37. The method of claim 36, wherein said phosphatidylcholine is derived from egg lecithin.

38. The method of claim 34, wherein said choline is administered in combination with one or more polyunsaturated fatty acids selected from the group consisting of arachidonic acid and docosahexaenoic acid.

39. The method of claim 38, wherein said choline is administered in combination with arachidonic acid and docosahexaenoic acid to give from about 150 to about 1200 $\mu$ mole of choline; from about 5.0mg to about 40mg arachidonic acid; and from about 1.5mg to about 20mg docosahexaenoic acid per kg per day.

40. A process for the production of an enteral formula comprising egg yolk phospholipids, said process comprising the steps of:



- (a) providing dried egg phosphatide powder essentially free of cholesterol;
- (b) dispersing said phospholipid fraction in an aqueous phase to form a phospholipid dispersion; and
- (c) combining said phospholipid dispersion with slurries of other components of said enteral formula.

41. The process according to claim 40, wherein said dispersion in aqueous phase provides egg phosphatide at about 2 to about 15wt%.

42. The process according to claim 41, wherein said dispersing in aqueous phase comprises adding the egg phosphatide powder to water at about 20 to 50°C.

43. A process for the production of an enteral formula comprising egg yolk phospholipids, said process being substantially as hereinbefore described with reference to any one of the examples.

44. An enteral formula produced by the process of any one of claims 40 to 43.

45. An improved enteral formula containing arachidonic acid and docosahexaenoic acid, characterised in that said arachidonic and docosahexaenoic acids are in the form of phospholipids, said enteral formula produced by a process comprising the steps of:

- (a) forming a 2-15wt% aqueous dispersion of said phospholipid;
- (b) subjecting said dispersion to de-aeration;
- (c) combining said de-aerated dispersion with at least one member selected from the group of protein, carbohydrate, vitamins and minerals to form said enteral formula; and
- (d) homogenising said enteral formula.

46. An improved enteral formula containing arachidonic acid and docosahexaenoic acid, characterised in that said arachidonic and docosahexaenoic acids are in the form of phospholipids, said enteral formula being substantially as hereinbefore described with reference to any one of the examples.

47. A formula suitable for feeding infants, comprising protein, carbohydrates and lipids, the improvement characterised in a lipid blend comprising medium chain triglycerides and egg phospholipid, wherein said egg phospholipid is present at a level from about 1wt% to about 40wt% of the lipid blend and wherein said egg phospholipid is essentially free of cholesterol.

48. The formula according to claim 47, wherein the egg phospholipid is present at a level of from 5 to 30wt% of the lipid blend.



49. The formula according to claim 47, further comprising arachidonic acid in a concentration of from about 10 to about 31 mg per 100kcal.

50. The formula according to claim 49, further comprising docosahexaenoic acid in a concentration of from about 3 to about 16 mg per 100kcal.

51. The formula according to claim 50, wherein said arachidonic acid and docosahexaenoic acid are present in a ratio of about 4:1 to about 2:1.

52. A formula suitable for feeding infants, said formula being substantially as hereinbefore described with reference to any one of the examples.

53. The use of one or more ingredients selected from the group consisting of:

- (a) at least one n-6 polyunsaturated fatty acid,
- (b) optionally, at least one n-3 polyunsaturated fatty acid,
- (c) at least one phospholipid, and
- (d) choline

in the preparation of a composition for reducing the incidence of necrotizing enterocolitis in an infant which is susceptible to necrotizing enterocolitis, wherein said ingredient is present at an effective amount in a daily dose of said composition.

54. The use according to claim 53 wherein said at least one n-6 polyunsaturated fatty acid includes arachidonic acid, and wherein said optional n-3 polyunsaturated fatty acid comprises docosahexaenoic acid.

55. The use according to claim 53 or 54 wherein said composition is an enteral composition.

56. The use according to claim 53 or 54 wherein said composition is a parenteral composition.

57. The use according to claim 55 wherein said composition is an enteral composition containing arachidonic acid and docosahexaenoic acid in effective amounts to deliver about 1.0 to about 60 mg per kg per day of arachidonic acid and about 0.25 to about 35 mg per kg per day of docosahexaenoic.

58. The use according to claim 55 wherein the weight ratio of arachidonic acid to docosahexaenoic acid ranges from about 2 to about 4.

59. The use according to claim 53 wherein said n-6 polyunsaturated fatty acid and said n-3 polyunsaturated fatty acid are long chain fatty acids independently selected from one or more sources selected from the group consisting of egg lecithin, fungal oils, algal oils and marine oils.

60. The use according to claim 53 or 54 wherein said n-6 polyunsaturated fatty acid and said n-3 polyunsaturated fatty acid are used in the form of phospholipids.



61. The use according to claim 56 wherein said parenteral solution comprises at least 20mg of arachidonic acid per liter and at least 10mg of docosahexaenoic acid per liter; and preferably comprises per liter about 20-200 mg of arachidonic and about 10-50mg of docosahexaenoic acid.

62. The use according to claim 53, wherein said composition further comprises protein, carbohydrate and phospholipids to provide in a daily dose at least 2.0mg of n-6 polyunsaturated fatty acids per kg per day, and at least 0.5mg of said optional n-3 polyunsaturated fatty acids per kg per day.

63. The use according to claim 62 wherein said composition provides at least 2.0mg arachidonic acid and at least 0.5mg docosahexaenoic acid per kg per day.

64. The use according to claim 63 wherein said enteral composition comprises egg phospholipid.

65. The use of claim 53 comprising use of phospholipids in said composition in effective daily amounts to provide between about 60 and about 2400 $\mu$ moles of phospholipids per kg per day; preferably between about 200 and about 1500 $\mu$ moles of phospholipids per kg per day.

66. The use of claim 65 wherein said phospholipids are derived from egg lecithin.

67. The use of claim 66 wherein said phospholipids are used in combination with one or more polyunsaturated fatty acids selected from the group consisting of arachidonic acid and docosahexaenoic acid, preferably to give from about 200 to about 1500 $\mu$ moles of phospholipid; from about 5.0mg to about 40mg arachidonic acid; and from about 1.5mg to about 20mg docosahexaenoic acid per kg per day.

68. The use of claim 53 comprising use of choline in said composition in effective daily amounts to provide between about 60 and about 1800 $\mu$ moles of choline per kg per day, preferably between about 150 and about 1200 $\mu$ moles of choline per kg per day.

69. The use of claim 68 wherein said choline is in the form of phosphatidylcholine, preferably derived from egg lecithin.

70. The use of claim 68 wherein said choline is used in combination with one or more polyunsaturated fatty acids selected from the group consisting of arachidonic acid and docosahexaenoic acid, preferably to give from about 150 to about 1200 $\mu$ moles of choline; from about 5.0mg to about 40mg arachidonic acid; and from about 1.5mg to about 20mg docosahexaenoic acid per kg per day.

71. The n-6 polyunsaturated fatty acid when used according to claim 2, wherein said at least one n-6 polyunsaturated fatty acid includes arachidonic acid.



72. The n-6 polyunsaturated fatty acid when used according to claim 71, wherein said use comprises administration and said administration is performed enterally.

73. The n-6 polyunsaturated fatty acid when used according to claim 71, wherein said use comprises administration and said administration is performed parenterally.

74. The n-6 polyunsaturated fatty acid when used according to any one of claims 2, 71, 72 or 73, wherein said use comprises administration and wherein said at least one n-6 polyunsaturated fatty acid is administered in combination with at least one n-3 polyunsaturated fatty acid.

75. The n-6 polyunsaturated fatty acid when used according to claim 74, wherein said n-3 polyunsaturated fatty acid comprises docosahexaenoic acid.

76. The n-6 polyunsaturated fatty acid when used according to claim 74, wherein said n-6 polyunsaturated fatty acid comprises arachidonic acid and said n-3 polyunsaturated fatty acid comprises docosahexaenoic acid.

77. The n-6 polyunsaturated fatty acid when used according to claim 76, wherein said administration is performed by feeding a sufficient amount of an enteral composition containing arachidonic acid and docosahexaenoic acid to deliver to said infant about 1.0 to about 60mg per kg per day of arachidonic acid and about 0.25 to about 35mg per kg per day of docosahexaenoic acid.

78. The n-6 polyunsaturated fatty acid when used according to claim 77, wherein the weight ratio of arachidonic acid to docosahexaenoic acid ranges from about 2 to about 4.

79. The n-6 polyunsaturated fatty acid when used according to claim 74, wherein said n-6 polyunsaturated fatty acid and said n-3 polyunsaturated fatty acid are long chain fatty acids independently selected from one or more sources selected from the group consisting of egg lecithin, fungal oils, algal oils and marine oils.

80. The n-6 polyunsaturated fatty acid when used according to claim 74, wherein said n-6 polyunsaturated fatty acid and said n-3 polyunsaturated fatty acid are in the form of phospholipids.

81. The n-6 polyunsaturated fatty acid when used according to claim 73, wherein a parenteral solution is administered and wherein said parenteral solution comprises at least 20mg of arachidonic acid per litre and at least 10mg of docosahexaenoic acid per litre.

82. The n-6 polyunsaturated fatty acid when used according to claim 81, wherein said solution comprises per litre about 20-200mg of arachidonic and about 10-50mg of docosahexaenoic acid.



83. The n-6 polyunsaturated fatty acid when used according to any one of claims 2. 71 to 82, comprising feeding to said infant a sufficient quantity of an enteral nutritional composition containing protein, carbohydrate and phospholipids to provide at least 2.0mg of n-6 polyunsaturated fatty acids per kg per day.

84. The n-6 polyunsaturated fatty acid when used according to claim 83, wherein said feeding further provides at least 0.5mg n-3 polyunsaturated fatty acids per kg per day.

85. The n-6 polyunsaturated fatty acid when used according to claim 84, wherein said feeding provides at least 2.0mg arachidonic acid and at least 0.5mg docosahexaenoic acid per kg per day.

86. The n-6 polyunsaturated fatty acid when used according to claim 85, wherein said enteral composition comprises egg phospholipid.

87. Use of at least one n-6 polyunsaturated fatty acid, in the manufacture of a medicament or enteral formula for reducing the incidence of necrotising enterocolitis in an infant.

88. The use according to claim 87 wherein said at least one n-6 polyunsaturated fatty acid includes arachidonic acid.

89. The use according to claim 88, wherein said manufacture is of an enteral formula.

90. The use according to claim 88, wherein said manufacture is of a medicament for parenteral administration.

91. The use according to claim 87, wherein said medicament or formula comprises said at least one n-6 polyunsaturated fatty acid in combination with at least one n-3 polyunsaturated fatty acid.

92. The use according to claim 91, wherein said n-3 polyunsaturated fatty acid comprises docosahexaenoic acid.

93. The use according to claim 91, wherein said n-6 polyunsaturated fatty acid comprises arachidonic acid and said n-3 polyunsaturated fatty acid comprises docosahexaenoic acid.

94. The use according to claim 93, wherein the weight ratio of arachidonic acid to docosahexaenoic acid ranges from about 2 to about 4.

95. The use according to claim 91, wherein said n-6 polyunsaturated fatty acid and said n-3 polyunsaturated fatty acid are long chain fatty acids independently selected from one or more sources selected from the group consisting of egg lecithin, fungal oils, algal oils and marine oils.



96. The use according to claim 91, wherein said n-6 polyunsaturated fatty acid and said n-3 polyunsaturated fatty acid are in the form of phospholipids.

97. The use according to claim 90, wherein said medicament is a parenteral solution which comprises at least 20mg of arachidonic acid per litre and at least 10mg of docosahexaenoic acid per litre.

98. The use according to claim 97, wherein said solution comprises per litre about 20-200mg of arachidonic and about 10-50mg of docosahexaenoic acid.

99. The use according to claim 87, wherein said enteral formula comprises egg phospholipid.

100. The use of claim 24, wherein said phospholipids are derived from egg lecithin.

101. The use of claim 24, wherein said phospholipids are in combination with one or more polyunsaturated fatty acids selected from the group consisting of arachidonic acid and docosahexaenoic acid.

102. The phospholipid when used of claim 22, said when used comprising when administering a sufficient quantity of said nutritional composition to provide between about 60 and about 2400 $\mu$ mole of phospholipids per kg day.

103. The phospholipid when used of claim 102, said when used comprising when administering a sufficient quantity of said nutritional composition to provide between about 200 and about 1500 $\mu$ mole of phospholipids per kg per day.

104. The phospholipid when used of claims 102 or 103, wherein said phospholipids are derived from egg lecithin.

105. The phospholipid when used of claim 102, wherein said phospholipids are administered in combination with one or more polyunsaturated fatty acids selected from the group consisting of arachidonic acid and docosahexaenoic acid.

106. The phospholipid when used of claim 105, wherein said phospholipids are administered in combination with arachidonic acid and docosahexaenoic acid to give from about 200 to about 1500 $\mu$ mole of phospholipid; from about 5.0mg to about 40mg arachidonic acid; and from about 1.5mg to about 20mg docosahexaenoic acid per kg per day.

107. Choline when used of claim 31, wherein said when used comprises when administering a nutritional composition containing said choline in a sufficient quantity to provide between about 60 and about 1800 $\mu$ moles of choline per kg per day.



108. Choline when used of claim 107, wherein said when used comprises when administering a sufficient quantity of said nutritional composition to provide between about 150 and about 1200 $\mu$ mole of choline per kg per day.

109. Choline when used of claim 31, wherein said choline is in the form of phosphatidylcholine.

110. Choline when used of claim 109, wherein said phosphatidylcholine is derived from egg lecithin.

111. Choline when used of claim 107, wherein said choline is administered in combination with one or more polyunsaturated fatty acids selected from the group consisting of arachidonic acid and docosahexaenoic acid.

112. Choline when used of claim 111, wherein said choline is administered in combination with arachidonic acid and docosahexaenoic acid to give from about 150 to about 1200 $\mu$ mole of choline; from about 5.0mg to about 40mg arachidonic acid; and from about 1.5mg to about 20mg docosahexaenoic acid per kg per day

113. The use of claim 33, wherein said choline is in the form of phosphatidylcholine.

114. The use of claim 113, wherein said phosphatidylcholine is derived from egg lecithin.

115. The use of claim 33, wherein said choline is in combination with one or more polyunsaturated fatty acids selected from the group consisting of arachidonic acid and docosahexaenoic acid.

**Dated 2 March, 2001**

**Abbott Laboratories**

**The University of Tennessee Research Corporation**

**Patent Attorneys for the Applicant/Nominated Person**

**SPRUSON & FERGUSON**

